Article
Multidisciplinary Sciences
Brendan Sullivan, Taylor Light, Vinh Vu, Adrian Kapustka, Kalina Hristova, Deborah Leckband
Summary: This study reveals a force-transduction mechanism that connects mechanical perturbations of E-cadherin to the activation of EGFR, a key regulator of cell proliferation. The results demonstrate that E-cadherin and EGFR form complexes at the plasma membrane, which are disrupted by the application of force or the presence of EGF. The findings provide insights into the initial steps of E-cadherin-mediated force transduction and the activation of growth regulatory signaling cascades.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Oncology
Rafael G. Amado, Michael Wolf, Marc Peeters, Eric Van Cutsem, Salvatore Siena, Daniel J. Freeman, Todd Juan, Robert Sikorski, Sid Suggs, Robert Radinsky, Scott D. Patterson, David D. Chang
Summary: The purpose of this study is to determine the impact of KRAS gene mutations on the efficacy of panitumumab monotherapy for metastatic colorectal cancer (mCRC). Through testing on 463 patients, it was found that 43% of patients had KRAS mutations. The results showed that panitumumab significantly improved overall survival and progression-free survival for patients with wild-type KRAS, while no significant efficacy was observed for patients with KRAS mutations. Therefore, KRAS status should be taken into account when selecting mCRC patients for panitumumab monotherapy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Tianyu Zeng, Hai Xu, Yincheng Liu, Chunxiao Sun, Fan Yang, Yan Liang, Xiang Huang, Ziyi Fu, Wei Li, Yongmei Yin
Summary: This study assessed the frequency of lung cancer following breast cancer diagnosis and the associations between the two types of cancer. The results showed that breast cancer patients, especially those with low-grade malignancy, have a higher risk of developing primary lung cancer. Close follow-up is recommended for patients with isolated ground-glass nodules and high-risk factors. Additionally, EGFR may play an important role in primary lung adenocarcinomas and breast cancer.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Yoshitaka Saito, Kazuki Uchiyama, Yoh Takekuma, Yoshito Komatsu, Mitsuru Sugawara
Summary: A retrospective evaluation of mCRC patients receiving anti-EGFR monoclonal antibody treatment identified liver metastasis as an independent risk factor for skin toxicities and prophylactic administration of antibiotics as a preventive factor. The study suggests that preemptive antibiotic use can decrease the risk of skin toxicities during anti-EGFR treatment.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Oncology
Muhammet Ozer, Suleyman Yasin Goksu, Nina Niu Sanford, Chul Ahn, Muhammad Shaalan Beg, Syed Mohammad Ali Kazmi
Summary: The study found that in patients with metastatic colorectal cancer, the presence of KRAS mutations is associated with survival rates in different age groups; the older the age, the less prognostic value KRAS mutations have on survival rate.
Article
Medicine, General & Internal
Ida H. Hiemstra, Kim C. M. Santegoets, Maarten L. Janmaat, Bart E. C. G. De Goeij, Wessel Ten Hagen, Sanne van Dooremalen, Peter Boross, Jeroen van den Brakel, Sieto Bosgra, Grietje Andringa, Berris van Kessel-Welmers, Dennis Verzijl, Richard G. Hibbert, Kristine A. Frerichs, Tuna Mutis, Niels W. C. J. van de Donk, Tahamtan Ahmadi, David Satijn, A. Kate Sasser, Esther C. W. Breij
Summary: The study found that HexaBody-CD38 can bind to CD38 and induce potent cytotoxicity in multiple myeloma (MM), acute myeloid leukemia (AML), and B-cell non-Hodgkin lymphoma (B-NHL) cells. Compared to daratumumab, HexaBody-CD38 showed enhanced cytotoxicity in cell lines with lower levels of CD38 expression, without increasing lysis of healthy leukocytes. In addition, HexaBody-CD38 can efficiently induce antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), trogocytosis, and apoptosis. The study also found that HexaBody-CD38 strongly inhibits CD38 cyclase activity, which may relieve immune suppression in the tumor microenvironment.
Article
Biochemistry & Molecular Biology
Elena Daveri, Ana M. Adamo, Eugenia Alfine, Wei Zhu, Patricia Oteiza
Summary: The study found that hexameric PAC can inhibit proliferation and promote apoptosis of colorectal cancer cells by reducing the activity of the EGFR signaling pathway. It affects EGFR localization, promotes EGFR internalization, and synergizes with EGFR-targeted drugs, demonstrating anti-CRC effects.
Review
Oncology
Laura A. Huppert, Ozge Gumusay, Dame Idossa, Hope S. Rugo
Summary: HR-positive/HER2-negative breast cancer is characterized by the presence of estrogen receptor and/or progesterone receptor and the absence of HER2 gene amplification. It accounts for a significant proportion of breast cancers and is treated with endocrine therapy. Combining endocrine therapy with cyclin-dependent kinase inhibitors has shown promising results in reducing recurrence and improving survival. Chemotherapy is used based on the stage and tumor biology. New therapies, such as novel endocrine agents and antibody-drug conjugates, are changing the treatment landscape.
CA-A CANCER JOURNAL FOR CLINICIANS
(2023)
Article
Medicine, Research & Experimental
Sha-Sha Hu, Yue Han, Tian-Yuan Tan, Hui Chen, Jia-Wen Gao, Lan Wang, Min-Hui Yang, Li Zhao, Yi-Qing Wang, Yan-Qing Ding, Shuang Wang
Summary: Emerging evidence shows that targeting glutamine metabolism may be a promising therapeutic strategy for KRAS-mutant colorectal cancer (CRC). In this study, researchers discovered that solute carrier 25 member 21 (SLC25A21) depletion accelerated the growth and metastasis of KRAS-mutant CRC cells by inhibiting Gln-derived alpha-ketoglutarate (alpha-KG) efflux from mitochondria, leading to increased GTP availability for persistent KRAS activation. Restoring SLC25A21 expression impaired cetuximab resistance in KRAS-mutant CRC.
Article
Oncology
Mengkai Yang, Tao Zhang, Yangfeng Zhang, Xiaojun Ma, Jing Han, Ke Zeng, Yafei Jiang, Zongyi Wang, Zhuoying Wang, Jing Xu, Yingqi Hua, Zhengdong Cai, Wei Sun
Summary: The study revealed that MYLK4 promotes the growth and metastasis of osteosarcoma by activating the EGFR signaling pathway. Additionally, the combination of MYLK4 and EGFR inhibitors showed synergistic effects on the growth and metastasis of OS in vitro and in vivo.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Luiz Henrique Araujo, Bianca Mendes Souza, Laura Rabelo Leite, Sabrina A. F. Parma, Natalia P. Lopes, Frederico S. V. Malta, Maira C. M. Freire
Summary: KRAS G12C mutation frequency is higher than other driver mutations in colorectal and non-small cell lung cancer, suggesting KRAS testing should be considered for all patients regardless of clinical or demographic characteristics.
Article
Biology
Yongjian Huang, Jana Ognjenovic, Deepti Karandur, Kate Miller, Alan Merk, Sriram Subramaniam, John Kuriyan
Summary: Research has shown that the EGFR receptor can adopt different conformations of the extracellular module when binding to different ligands, with implications for intracellular signaling pathways.
Article
Multidisciplinary Sciences
Nina E. Weisser, Mario Sanches, Eric Escobar-Cabrera, Jason O'Toole, Elizabeth Whalen, Peter W. Y. Chan, Grant Wickman, Libin Abraham, Kate Choi, Bryant Harbourne, Antonios Samiotakis, Andrea Hernandez Rojas, Gesa Volkers, Jodi Wong, Claire E. Atkinson, Jason Baardsnes, Liam J. Worrall, Duncan Browman, Emma E. Smith, Priya Baichoo, Chi Wing Cheng, Joy Guedia, Sohyeong Kang, Abhishek Mukhopadhyay, Lisa Newhook, Anders Ohrn, Prajwal Raghunatha, Matteo Zago-Schmitt, Joseph D. Schrag, Joel Smith, Patricia Zwierzchowski, Joshua M. Scurll, Vincent Fung, Sonia Black, Natalie C. J. Strynadka, Michael R. Gold, Leonard G. Presta, Gordon Ng, Surjit Dixit
Summary: In this study, the authors engineered an anti-HER2 biparatopic antibody, zanidatamab, with multiple mechanisms of action, including induction of HER2 clustering to trigger complement-dependent cytotoxicity, signal inhibition, antibody-dependent cellular cytotoxicity, and phagocytosis. Zanidatamab showed superior in vivo antitumor activity compared to tras + pert in a HER2-expressing xenograft model.
NATURE COMMUNICATIONS
(2023)
Review
Gastroenterology & Hepatology
Ming-He Zhao, Ai-Wen Wu
Summary: In this review, we summarized current approaches for combination therapy to alleviate resistance to KRAS G12C inhibitors in colorectal cancer, with a focus on the mechanisms of therapeutic resistance.
GASTROENTEROLOGY REPORT
(2023)
Article
Oncology
Samuel A. Jacobs, James J. Lee, Thomas J. George, James L. Wade, Philip J. Stella, Ding Wang, Ashwin R. Sama, Fanny Piette, Katherine L. Pogue-Geile, Rim S. Kim, Patrick G. Gavin, Corey Lipchik, Huichen Feng, Ying Wang, Melanie Finnigan, Brian F. Kiesel, Jan H. Beumer, Norman Wolmark, Peter C. Lucas, Carmen J. Allegra, Ashok Srinivasan
Summary: This study aimed to determine the recommended phase II dose and efficacy of neratinib combined with cetuximab in patients with metastatic colorectal cancer, particularly those who were resistant to anti-EGFR therapy. The study found that the recommended dose of neratinib in this combination therapy was well tolerated with a low incidence of adverse events, and while there were no objective responses, stable disease was observed at all neratinib doses. Additionally, HER2 amplification was more frequently detected in tissue and blood samples post-anti-EGFR therapy.
CLINICAL CANCER RESEARCH
(2021)
Article
Endocrinology & Metabolism
Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Angela Lamarca, Jorge Barriuso, Angel Castano, Marta Benavent, Vicente Alonso, Maria del Carmen Riesco, Teresa Alonso-Gordoa, Ana Custodio, Manuel Sanchez Canovas, Jorge Hernando, Carlos Lopez, Adelaida La Casta, Ana Fernandez Montes, Monica Marazuela, Guillermo Crespo, Jose Angel Diaz, Eduardo Feliciangeli, Javier Gallego, Marta Llanos, Angel Segura, Felip Vilardell, Juan Carlos Percovich, Enrique Grande, Jaume Capdevila, Juan Valle, Rocio Garcia-Carbonero
Summary: This study evaluated the external validity of RCTs examining SSAs in the real world, as well as the main effect-modifying factors. The results indicate that both octreotide LAR and lanreotide autogel had a similar effect on PFS, making them valid alternatives in patients with well-differentiated, metastatic GEP-NENs.
NEUROENDOCRINOLOGY
(2022)
Article
Oncology
Antoine Italiano, Philippe A. Cassier, Chia-Chi Lin, Tuomo Alanko, Katriina J. Peltola, Anas Gazzah, Her-Shyong Shiah, Emiliano Calvo, Andres Cervantes, Desamparados Roda, Diego Tosi, Bo Gao, Michael Millward, Lydia Warburton, Minna Tanner, Stefan Englert, Stacie Lambert, Apurvasena Parikh, Daniel E. Afar, Gregory Vosganian, Victor Moreno
Summary: This study presents the safety, efficacy, pharmacokinetic, and pharmacodynamic data of budigalimab in head and neck squamous cell carcinoma and non-small cell lung cancer patients. Results showed that the drug's profiles are similar to other PD-1 inhibitors, and development in combination with novel anticancer agents is ongoing. The objective response rates and median progression-free survival varied slightly between the HNSCC and NSCLC cohorts.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Oncology
Yolanda Andreu, Paula Martinez, Ana Soto-Rubio, Silvia Fernandez, Carles Bosch, Andres Cervantes
Summary: This study aimed to determine the prevalence of distress and unmet supportive care needs in post-treatment colorectal cancer (CRC) survivors. Findings showed that one in five CRC survivors had clinical distress and 86% expressed at least one unmet need. The risk factors associated with this included lower socioeconomic status, younger age, and a primary treatment that includes more than surgery.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Oncology
Tenna Vesterman Henriksen, Noelia Tarazona, Amanda Frydendahl, Thomas Reinert, Francisco Gimeno-Valiente, Juan Antonio Carbonell-Asins, Shruti Sharma, Derrick Renner, Dina Hafez, Desamparados Roda, Marisol Huerta, Susana Rosello, Anders Husted Madsen, Uffe S. Love, Per Vadgaard Andersen, Ole Thorlacius-Ussing, Lene Hjerrild Iversen, Kare Andersson Gotschalck, Himanshu Sethi, Alexey Aleshin, Andres Cervantes, Claus Lindbjerg Andersen
Summary: The study demonstrates the strong prognostic value of serial postoperative ctDNA analysis in predicting recurrence and assessing tumor growth rate. The novel combination of ctDNA detection and growth rate assessment provides unique opportunities for guiding treatment decisions.
CLINICAL CANCER RESEARCH
(2022)
Correction
Oncology
Nicola Fazio, Lorenzo Gervaso, Thorvardur R. Halfdanarson, Anna La Salvia, Johannes Hofland, Jorge Hernando, Mohamad B. Sonbol, Rocio Garcia-Carbonero, Jaume Capdevila, Wouter W. de Herder, Anna Koumarianou, Gregory Kaltsas, Maura Rossi, Simona Grozinsky-Glasberg, Kira Oleinikov, Sabrina Boselli, Darina Tamayo, Vincenzo Bagnardi, Alice Laffi, Manila Rubino, Francesca Spada
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Miriam Koopman, Carmine Pinto, Gyorgy Bodoky, Rocio Garcia-Carbonero, Francisca Marti Marti, Jean-Baptiste Bachet
Summary: The PROMETCO study is an international real-world research collecting data on metastatic colorectal cancer patients. The study aims to investigate the treatment progressions and clinical outcomes of patients. Data from 544 patients across 18 countries have been collected and will be followed for at least 18 months.
Article
Oncology
Paula Montero, Martin Perez-Leal, Jose Alejandro Perez-Fidalgo, Celia Sanz, Cristina Estornut, Ines Roger, Javier Milara, Andres Cervantes, Julio Cortijo
Summary: Skin toxicity caused by paclitaxel could be underestimated as the adverse events may appear asymptomatic. This study found that paclitaxel alters gene and protein expression related to skin markers, and impairs the physical, physiological, and biomechanical properties of the skin in gynecological cancer patients. Prophylactic measures should be taken to prevent these subclinical alterations and potential adverse reactions.
Article
Oncology
Maria Alsina, Josep Tabernero, Marc Diez
Summary: Gastric cancer is a global healthcare problem with multiple symptoms and fragility in patients. Multidisciplinary teams are required for palliative care and nutritional support. Sequential treatment is the best approach, and a third-line treatment can improve survival and quality of life.
Article
Oncology
Chiara Bellio, Marta Emperador, Pol Castellano, Albert Gris-Oliver, Francesc Canals, Alex Sanchez-Pla, Esther Zamora, Joaquin Arribas, Cristina Saura, Violeta Serra, Josep Tabernero, Bruce A. Littlefield, Josep Villanueva
Summary: Drug tolerant persister (DTP) cells enter a reversible slow-cycling state after treatment, with GDF15 identified as a key protein over-secreted and essential for their survival. Combining eribulin with an anti-GDF15 antibody may be effective in targeting and killing breast cancer DTP cells.
Article
Oncology
Tessa Suzanne van Schooten, Sarah Derks, Elena Jimenez-Marti, Fatima Carneiro, Ceu Figueiredo, Erika Ruiz, Maria Alsina, Cristina Molero, Marcelo Garrido, Arnoldo Riquelme, Carmelo Caballero, Eva Lezcano, Juan Manuel O'Connor, Federico Esteso, Judith Farres, Jose Manuel Mas, Florian Lordick, Jeannette Vogt, Antonella Cardone, Charis Girvalaki, Andres Cervantes, Tania Fleitas
Summary: The LEGACy study is a multi-institutional research project aimed at filling the knowledge gap on gastric cancer in European and Latin American countries. It will generate novel knowledge on tumor biology characteristics by integrating epidemiological, multi-omics, and clinical data, and develop and validate cost-effective clinical decision-making methods.
Article
Health Care Sciences & Services
Federica Papaccio, Manuel Cabeza-Segura, Blanca Garcia-Mico, Noelia Tarazona, Desamparados Roda, Josefa Castillo, Andres Cervantes
Summary: Precision medicine approaches for solid tumors, mainly based on genomics, have shown limited success. Factors such as gene expression, genomic alterations, and the tumor microenvironment can all influence the response, making a genomics-only approach insufficient. However, the implementation of patient-derived organoids shows promise in predicting patient response to drug treatment.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Jorge Sancho-Muriel, Francisco Giner, Hanna Cholewa, Alvaro Garcia-Granero, Susana Rosello, Blas Flor-Lorente, Andres Cervantes, Eduardo Garcia-Granero, Matteo Frasson
Summary: The aim of this study was to evaluate the prognostic value of a novel variable, the percentage of mesorectal infiltration (PMI), in pT3 rectal cancer. The results showed that PMI was significantly associated with oncological outcomes such as local recurrence, overall recurrence, and overall survival. A PMI >60% can be used as a cut-off value for subclassifying pT3 rectal tumors and may impact decision-making in adjuvant treatment and follow-up schedule.
COLORECTAL DISEASE
(2023)
Review
Oncology
Nadia Saoudi Gonzalez, Francesc Salva, Javier Ros, Iosune Baraibar, Marta Rodriguez-Castells, Ariadna Garcia, Adriana Alcaraz, Sharela Vega, Sergio Bueno, Josep Tabernero, Elena Elez
Summary: Metastatic colorectal cancer is a complex and life-threatening disease influenced by various factors. Tumor heterogeneity, caused by genetic and non-genetic factors, affects tumor development and therapy effectiveness. Computational analysis of next-generation sequencing and real-time monitoring of circulating tumor DNA are valuable tools in understanding tumor evolution and heterogeneity.
News Item
Oncology
V. Gambardella, F. Gimeno-Valiente, S. Rosello, A. Cervantes
Article
Oncology
Marta Albanell-Fernandez, Sara S. Oltra, Marta Orts-Arroyo, Maider Ibarrola-Villava, Fany Carrasco, Elena Jimenez-Marti, Andres Cervantes, Isabel Castro, Jose Martinez-Lillo, Gloria Ribas
Summary: To overcome limitations of platinum-based chemotherapy, new active metallodrugs based on other transition metals are being researched. Runat-BI, a ruthenium-based compound, showed selectivity for tumoral cells and reduced tumor growth and migration in three cancer cell lines. Its mechanism of action is related to DNA synthesis and it also increases expression of proapoptotic genes. Runat-BI has potential as an anticancer therapy, but further studies are needed to understand its full potential and mechanism of action.
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)